Tromsø, Norway, 04 April 2019 – Biotec Pharmacon’s (OSE: Biotec) subsidiary, Biotec BetaGlucans, has renewed its M-Glucan® contract with its largest customer within its Animal Health business.
The Company will continue to supply and assist its long-standing customer, a major player in the Animal Health sector. Expected revenues, depending on the sales of the customer to its end-users, are approximately NOK 20m annually.
Using beta-glucans to safely and effectively enhance the immune system of farmed animals has been a core activity for Biotec Pharmacon for 30 years. The M-Glucan® product has a variety of applications to improve animals’ resistance to disease and to strengthen their growth rate. Biotec Pharmacon’s beta-glucan product is well-documented in the animal feed industry. It is supported by over 60 publications and numerous animal trials – including fish and a variety of mammals – verifying its safety and mechanism of action.
Christian Jørgensen, CEO, said:
“We are proud to continue our long-term business relationship with this highly respected supplier of animal feed. It confirms not only the quality of our products, but also that our organization can operate and compete at the highest level in this sector.”
“This renewed contract has secured a steady revenue stream for Biotec going forward.”